Q&A: Improving Viral Vector Production Through Addressing Complexity

Viral vectors remain the dominant gene delivery method, crucial for advancing cell and gene therapies. However, their manufacturing and commercialization present unique challenges. In a recent webinar, experts from Novartis Contract Manufacturing discussed the evolving landscape of viral vector production, emphasizing innovation in manufacturing, supply chain management, and regulatory compliance.

In the Q&A session, panelists highlighted emerging trends in analytical technologies for viral vector characterization, such as mass spectrometry, next-generation sequencing, and high-throughput fluorescence-based assays, all of which enhance quality control strategies.

Novartis’ approach to tech transfers ensures smooth integration of diverse platforms and proprietary technologies through structured knowledge transfer, expert training, and continuous technical support. Additionally, the shift from adherent to suspension cell culture was discussed, with suspension systems gaining traction due to scalability advantages, despite challenges in impurity profiles and process transitions. Novartis Contract Manufacturing offers its expertise to external partners, providing innovative solutions to streamline viral vector production and bring advanced gene therapies to patients worldwide.